Compare NNNN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | VNDA |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4M | 301.1M |
| IPO Year | 2023 | 2005 |
| Metric | NNNN | VNDA |
|---|---|---|
| Price | $4.90 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 199.7K | ★ 703.0K |
| Earning Date | 10-23-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $35.50 |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $4.66 | $4.27 |
| 52 Week High | $44.73 | $9.91 |
| Indicator | NNNN | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 28.21 | 30.43 |
| Support Level | N/A | $4.45 |
| Resistance Level | $6.95 | $5.37 |
| Average True Range (ATR) | 0.55 | 0.16 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 7.01 | 8.89 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.